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Background: Hormone-resistant (HR) prostate cancers are highly aggressive and respond poorly to treatment.
IL-6/STAT3 signaling has been identified to link with the transition of HR and aggressive tumor behavior. The role of
IL-6 in the radiation response of prostate cancer was investigated in the present study.
Material and methods: The murine prostate cancer cell line (TRAMP-C1) and the hormone-resistant cell sub-line,
TRAMP-HR, were used to assess the radiation response using in vitro clonogenic assays and tumor growth delay
in vivo. Biological changes following irradiation were investigated by means of experimental manipulation of IL-6
signaling. Correlations among IL-6 levels, tumor regrowth, angiogenesis and myeloid-derived suppressor cell
(MDSC) recruitment were examined in an animal model.
Results: HR prostate cancer cells had a higher expression of IL-6 and more activated STAT3, compared to TRAMP-
C1 cells. HR prostate cancer cells had a greater capacity to scavenge reactive oxygen species, suffered less
apoptosis, and subsequently were more likely to survive after irradiation. Moreover, IL-6 expression was positively
linked to irradiation and radiation resistance. IL-6 inhibition enhanced the radiation sensitivity of prostate cancer,
which was associated with increased p53, RT-induced ROS and oxidative DNA damage. Furthermore, when mice
were irradiated with a sub-lethal dose, inhibition of IL-6 protein expression attenuated angiogenesis, MDSC
recruitment, and decreased tumor regrowth.
Conclusion: These data demonstrate that IL-6 is important in the biological sequelae following irradiation.
Therefore, treatment with concurrent IL-6 inhibition is a potential therapeutic strategy for increasing the radiation
response of prostate cancer.
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Radiation therapy (RT) is an important treatment
modality for localized prostate cancer and leads to
improved local control and disease-free survival of pros-
tate cancer patients. Despite progress in the delivery
mode, loco-regional post-radiotherapy relapse still occurs
in a fraction of treated patients. Primarily the number of
clonogens, their intrinsic cellular radioresistance and
microenvironment factors determine the probability of
local tumor control following radiation therapy. In the
clinic, HR cancers usually appear highly aggressive and
responding poorly to treatment. Several mechanisms are
implicated in prostate cancer progression and androgen-* Correspondence: wucgmh@gmail.com
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reproduction in any medium, provided the orindependent growth [1,2]. Therefore, an improved under-
standing of the biological changes underlying the radiation
response of prostate cancer is an important issue.
In addition to directly damaging DNA [3], the radiation-
induced response is dynamic and involves several media-
tors and immune responses [4]. Inflammation provides a
favorable environment for cancer formation and progres-
sion has been widely accepted [5]. However, there is not
to detail the fundamental relationship between tumor
responses to radiation and inflammation. Several inflam-
matory cytokines are believed to play key roles in radiation
tolerance, and lead to tumor promotion, invasion, and
angiogenesis [6]. Irradiation induces up-regulation of the
levels of a variety of cytokines including IL-6, IL-8 and
TNF-alpha. IL-6, a multi-functional cytokine, is the main
activator of STAT3 signaling and the inducer for androgen. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reported to mediate the radioresistance of tumor [9], and
be up regulated by IL-6 [10]. Moreover, IL-6 has been
reported to increase in a variety of tumors, and contri-
butes to aggressive tumor growth and resistance to treat-
ment [11-13]. In patients with high IL-6 concentrations,
the response to treatment to chemotherapy and hormone
therapy was worse. Patients with higher IL-6 levels have a
shorter survival while a reduction in the level of IL-6 was
visible in patients who responded better to therapy
[14-16]. Furthermore, activated IL-6/STAT signaling is
arguably the main pathway that regulates expansion of
myeloid-derived suppressor cells (MDSC) [17]. The
increase in MDSC induced by local irradiation was
reported to facilitate tumor regrowth after irradiation [18].
Thus, IL-6 might represent a promising therapeutic target
for preventing radioresistance of cancer. We reported
previously that overexpressed IL-6 and activated STAT3
signaling are critical for aggressive tumor behavior and
the transition of HR prostate cancer [19,20]. However, the
role of IL-6 in the radiation response of prostate cancer
remains unclear. In the present study, we performed
cell-culture and immunocompetent animal experiments
to determine the correlation between IL-6 and the
biological consequences following irradiation including
tumor regrowth, angiogenesis and MDSC recruitment.
This investigation of the role of IL-6 in prostate cancer
might lead to new strategies of enhancing the radiation
response of prostate cancer.
Materials and methods
Cell culture and reagents
The TRAMP-C1 cell line, derived from the prostate
tumor of a PB-Tag C57BL/6 (the transgenic adenocar-
cinoma of the mouse prostate (TRAMP)) mouse, was
cultured in DMEM and 10 nM dehydroisoandrosterone.
TRAMP-C1 cells were serially passaged in androgen
deprived medium to establish androgen-independent
growth as TRAMP-HR. TRAMP-C1 and TRAMP-HR
cells were stably transfected with IL-6 silencing or control
vectors. We also cultured 22RV1-HR and LNCaP- HR
cells, as described earlier [21]. Mice recombinant IL-6 and
IL-6 antibody were purchased from R&D (Minneapolis,
MN). Stable IL-6–silenced cancer cells were generated by
transfecting TRAMP-C1 and TRAMP-HR cells with the
IL-6–silencing vector (IL-6 shRNA lentiviral transduction
Particles in the PLKO.1 vector backbone with puromycin
resistance) and selected by culturing in medium con-
taining puromycin for 4 weeks.
Tumor models (ectopic and orthotopic) in mice and
radiation
Eight week-old male C57BL/6 J mice were used as the
tumor implantation model, with the approval of theExperimental Animal Committee of our hospital. In the
ectopic tumor implantation model, TRAMP-C1 and
TRAMP-HR transfectants (1×106 cells per implantation,
five animals per group) were s.c. implanted into the
dorsal gluteal region. Radiosensitivities were indicated by
growth delay (i.e., after irradiation, the time required for
the tumor to recover to its previous volume). In the
orthotopic tumor implantation model, TRAMP-C1 and
TRAMP-HR transfectants (1×106 cells per implantation)
were intraoperatively implanted into the lateral region of
the prostate gland. The extent of orthotopic tumor
invasion was measured 3 weeks after implantation. The
assessment of the tumor invasion ability in vivo was to
evaluate if the implanted orthotopic tumor develope
extraprostatic extension including tumor fixed or inva-
ding adjacent structures). To investigate the effect of
IL-6 on tumor regrowth in tissue pre-irradiation, mice
were irradiated for 10-Gy to the lower abdomen and
extremities (including the prostate glands) 2 days before
tumor implantation. The details are provided in the
Additional file 1: Supplementary methods.
Clonogenic assays
To determine intrinsic cellular radiosensitivities, clonogenic
assays were performed. Exponentially growing cells were
irradiated and incubated for 10 days at 37°C. The plates
were stained with crystal violet (Sigma) to aid colony
counting. Colonies containing >50 cells were scored to
determine plating efficiency and the fractions of the cells
surviving after application of the various treatments.
MDSC flow cytometric analyses
MDSC are characterized by the co-expression of the
myeloid-cell lineage differentiation antigens GR1 and
CD11b [17]. Therefore, we used specific anti-Gr1 anti-
body, which reacts with a common epitope on Ly-6G
and Ly-6C, and an antibody specific for CD11b (BD
Pharmingen) to define mouse MDSCs as CD11b + Gr1+.
We performed FACS and immunofluorescence analyses
to examine the effect of irradiation on MDSC re-
cruitment 48 h after mice received irradiation as we
previously reported [22]. FACS was carried out on sin-
gle cell suspensions prepared from whole tumors and
spleen after digestion [23,24] and immunostaining for
CD11b and GR1 with fluorescence-labeled monoclonal
antibodies (BD PharMingen). The percentage of MDSC
was measured by multicolor flowcytometry with the
abovementioned monoclonal antibodies. Isotype-specific
antibodies were used as negative controls in FACS.
Immunohistochemical staining and immunofluorescence
for tissue specimens
Formalin-fixed, paraffin-embedded tissues were cut into
5-μm sections and mounted on slides for immunohis-
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were cut into 5- to 8-μm cryostat sections, and incu-
bated at room temperature for immunofluorescence
staining. The details are provided in the Additional file 1:
Supplementary methods.Intracellular free radical generation
2’7’-dichlorofluorescein diacetate (DCFH-DA) is an indi-
cator of intracellular H2O2 and free radical levels [25].
The levels of intracellular reactive oxygen species (ROS)
and oxidative DNA damage were examined after 30-min
irradiation. The details are provided in the Additional
file 1: Supplementary methods.Enzyme-linked immunosorbent assay (ELISA) of IL-6
in vitro and in vivo
IL-6 levels in culture supernatants and murine serum
samples were assessed using a Mouse IL-6 Quantikine
ELISA Kit (R&D Systems). The details are provided in
the Additional file 1: Supplementary methods.Figure 1 Radiation sensitivities of hormone-sensitive and HR prostate
6, or 9 Gy, and the survival curves were determined by colony-formation a
after irradiation exposure divided by the plating efficiency; (b) Tumor grow
growth delay after 15-Gy irradiation. HR tumors appeared more radioresista
tumor volume at each time point divided by that at irradiation respectively. E
P < 0.05. (c) The intracellular ROS level was measured, using the fluorescent d
Gy irradiation. Y-axis represents the relative level, normalized to the level of RO
using Annexin V staining for apoptosis in prostate cancer cells, either withoutImmunoblotting and statistical analysis
The details are provided in the Additional file 1:
Supplementary methods.
Results
Response to radiation treatment
Prostate cancer cells were exposed to single radiation
doses of 0, 3, 6 or 9 Gy and their survival determined by
colony formation assays. Figure 1a shows that HR cells
had significantly greater radio-resistance compared to
TRAMP-C1 cells. To determine radiation sensitivity
in vivo, 15-Gy irradiation was performed when ectopic
tumors in mice grew to a size of 0.5 cm3. The results
show that TRAMP-C1 subcutaneous tumors had a
longer-duration tumor growth delay after irradiation
compared to TRAMP-HR (Figure 1b). As ROS are
thought to be important mediators of radiation damage,
we assayed intracellular ROS in TRAMP-C1 and HR
cells 30 min after 9-Gy irradiation. Intracellular ROS
levels were lower in HR than in control cells with or
without irradiation (Figure 1c). Moreover, HR prostatecancer. (a) Cells (TRAMP-C1 and TRAMP-HR) were irradiated with 0, 3,
ssay. The survival fraction was determined by enumerating colonies
th delay of irradiated ectopic tumors. The radiosensitivity is shown as
nt, as shown by the shorter growth delay. Y-axis shows the ratio of
ach point is the mean of three independent experiments; bars, SD. *,
ye DCFH-DA, in prostate cancer cells either untreated or 30 min after 9-
S in TRAMP-C1 under control conditions. (d) Flow cytometric analysis
irradiation or 24 h after 9-Gy irradiation.
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pared to TRAMP-C1 cells, as revealed by annexin V and
PI staining (Figure 1d).
The role of IL-6 in the radiation sensitivity of prostate cancer
HR prostate cancer (LNCaP-HR and TRAMP-HR) had
higher levels of IL-6, more activated STAT3 and AR
compared to hormone sensitive prostate cancer cells
(LNCaP and TRAMP-C1) shown in our previous and
the present study [19]. We further examined the effect
of irradiation on IL-6/STAT3 signaling in prostate
cancer in the present study. Our data revealed that
irradiation enhanced IL-6 expression by Western blotting
and ELISA assay (Figure 2a), and IHC data from the irra-
diated ectopic tumors (Figure 2b) confirmed the in vitro
findings. To determine the role of IL-6 in the radiosensi-
tivity of prostate cancer, TRAMP-C1 and TRAMP-HR
were transfected with IL-6-silencing or control vectors.
The IL-6 silencing vector significantly inhibited IL-6
expression associated with decreased p-STAT3 (Figure 3a,Figure 2 Effects of irradiation on IL-6 expression. IL-6 and p-STAT3 leve
irradiation, and (b) IHC staining of ectopic tumors 48 h after 15-Gy irradiatiAdditional file 2: Figure S1). As shown in Figure 3a-c,
blocking of IL-6 increased the RT-induced loss of
clonogenic cells, which was associated with increased p53,
apoptosis, intracellular ROS, and oxidative DNA damage.
In vivo, IL-6 inhibition significantly prolonged the delay in
prostate tumor growth after irradiation (Figure 3d).
Furthermore, as shown in Figure 3e-f, IL-6 also possessed
a significant impact on the radiation sensitivity of human
LNCaP-HR and 22RV1-HR prostate cancer cells.
Tumor regrowth following irradiation
As shown in vivo, irradiation causes tumor inhibition,
but tumor regrowth after irradiation remains an import-
ant issue. To investigate this, we pre-irradiated extremity
tissue and the prostate gland of mice with a 10-Gy dose
before implanting prostate tumor cells to mimic tumor
regrowth after irradiation. HR exhibited more rapid
tumor growth and a higher ability to invade the sur-
rounding tissues as assessed by ectopic and orthotopic
tumors in pre-irradiated mice (Figure 4a-b). Angio-ls were evaluated by (a) Western blotting and ELISA 6 h after 9-Gy
on in vivo. Representative slides and quantitative data are shown.
Figure 3 (See legend on next page.)
Wu et al. Radiation Oncology 2013, 8:159 Page 5 of 11
http://www.ro-journal.com/content/8/1/159
(See figure on previous page.)
Figure 3 Effects of IL-6 on the radiosensitivity of prostate cancer. The IL-6–silencing vector significantly decreased IL-6 expression in tumor
cells after irradiation, as demonstrated by Western blotting in vitro, IHC in vivo (a). The effects of IL-6 on in vitro radiosensitivity were evaluated
using irradiated prostate cancer cells treated with vectors or IL-6–silencing vectors; (b) FACS with PI and Annexin V staining 24 h after 9-Gy
irradiation and clonogenic assays; (c) Intracellular ROS levels as measured by the fluorescent dye DCFH-DA in prostate cancer cells, and
immunofluorescence staining of oxidative DNA damage (DAPI, blue; 8-oxoG, red), 30 min after irradiation. Columns show the mean of three
independent experiments; bars, SD. *, P < 0.05. (d) Effects of IL-6 on in vivo radiosensitivity were evaluated by means of the growth delay of
ectopic prostate tumors following 15-Gy irradiation. Y-axis shows the tumor volume ratio at each time point, divided by that at the time of
irradiation. (CV = cells transfected with control vectors; IL-6 SV = cells transfected with IL-6 silencing vectors). The effects of IL-6 on the expressions
of activated STAT3, p53 and AR (e) and the sensitivity of radiation (f) were assessed using cells pre-incubated in the presence or absence of 5 ug/ml
IL-6 neutralizing antibody for 24 h.
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sion, and CD31-mediated endothelial cell–cell inter-
actions play a role in this process [26]. Furthermore, the
Ki-67 protein is a cellular marker of proliferation.
Figure 4c and Additional file 2: Figure S2, as determined
using Ki-67, CD31 and VEGF immunostaining, showed
that HR tumor growth in pre-irradiated tissue was associ-
ated with increased cell proliferation and angiogenesis com-
pared with the TRAMP-C1 tumor. Furthermore, IL-6–
silencing vectors significantly inhibited TRAMP-C1 and
HR tumor regrowth and invasion, which was associated
with attenuated expressions of angiogenic factors and
STAT3 activation. Therefore, we suggest that IL-6 inhib-
ition attenuates tumor regrowth after irradiation, an effect
associated with decreased cell proliferation and attenuation
of angiogenesis.Effect of IL-6 on MDSC induction
We reported previously that MDSC contributes to
tumor promotion in IL-6–positive prostate cancer, at
least in part. Moreover, the increase in MDSC induced
by local irradiation facilitates tumor regrowth after
irradiation [18]. Therefore, we examined the correlation
between IL-6 and MDSC recruitment after irradiation by
analyzing MDSC levels in tumor-bearing mice 48 h after
irradiation [10,22], with or without IL-6-silencing vectors.
The recruitment of CD11b +Gr1+ myeloid cells increased
significantly in mice bearing a HR tumor, compared to
that in TRAMP-C1 tumor, by FACS and immunofluores-
cence analyses, and recruitment of CD11b +Gr1+ cells to
tumors were augmented by irradiation (Figure 5a-b).
Furthermore, the IL-6 silencing vector significantly abro-
gated the recruitment of MDSC with or without irradia-
tion. To determine further whether MDSC accumulation
was driven by IL-6 stimulation, we examined MDSC levels
in tumors in pre-irradiated mice with or without IL-6
stimulation. As determined by FACS and immunofluores-
cence, IL-6 stimulation increased MDSC accumulation
(Figure 5c-d). These results suggested that IL-6 plays an
important role in the induction of MDSC recruitment,which might subsequently contribute to the increased
invasiveness of tumors that regrow after irradiation.
Discussion
The transgenic adenocarcinoma of the mouse prostate
(TRAMP) model closely mirrors the pathogenesis of
human prostate cancer. TRAMP-C1 is a prostate cell line
derived from a TRAMP tumor and widely used to assess
novel therapeutic approaches for prostate cancer. To
evaluate the radiation response in an immunocompetent
model, a TRAMP-C1 prostate cancer cell line, derived
from adenocarcinoma of the mouse prostate, and
TRAMP-HR, derived from TRAMP-C1 cells cultured in
androgen-deprived medium, were used in the present
study. The radiation response was evaluated using assays
that take into account various types of radiation-induced
cell death, specifically, in vitro clonogenic assays and
in vivo tumor size measurements. As determined by
clonogenic assay and tumor-growth delay in mice, HR cells
are more resistant to irradiation compared to TRAMP-C1
tumor cells. Ionizing radiation can induce various cell-
death processes, and the biological effects of RT are medi-
ated largely by reactive oxygen intermediates [27]. In this
study, elevated RT-induced apoptosis and a greater
increase in ROS were observed in TRAMP-C1 cells com-
pared with HR cells. It was reported that IL-6 contributed
to the conversion of prostate cancer to an androgen-
independent state in xenografts models [8,28], and anti-IL
-6 monoclonal antibody have been applied to treat meta-
static castration-resistant prostate cancer in clinical studies
[29]. Our data also showed that overexpressed IL-6 had
significant impact on androgen- independent growth and
aggressive behavior of prostate cancer. In prostate cancer,
although the critical role of IL-6 in carcinogenesis has been
highlighted [19,28], its role in the radiation response of
prostate cancer requires further investigation. IL-6 is an
important transcription factor that regulates oncogenic
signaling and induces STAT3 activation [30,31] in a
variety of malignancies by promoting proliferation and
inhibiting apoptosis. Moreover, IL-6 has also been corre-
lated with cancer treatment resistance where modulating
Figure 4 Tumor growth in mice following 10-Gy irradiation. The effect of IL-6 silencing vectors on tumor regrowth as demonstrated by (a)
ectopic tumor growth curves and representative images 12 days after tumor implantation in pre-irradiated mice. (b) Effect of the IL-6–silencing
vector on invasion was evaluated using the orthotopic tumor model. Representative images and quantitative data are shown. Y-axis represents
the relative ratio, normalized to the number of TRAMP-C1 tumors developing extraprostatic extension 3 weeks after implantation in pre-irradiated
mice.*, P < 0.05. (c) Expression levels of Ki-67, CD31, and VEGF were evaluated by immunofluorescence in growing tumors 12 days after
implantation in irradiated mice.
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to treatment, including breast cancer, ovarian cancer and
esophageal cancer [14-16]. In the present study, we
examined the role of IL-6 in the response to radiation
and tumor regrowth following radiation in prostate
cancer. Mechanisms underlying DNA repair and theDNA damage response (DDR) play key roles in the regula-
tion of radiation-induced cell death [32]. IL-6 is
reported play a role in DRR to suppress cell death
induced by treatment. IL-6 increases the expression of
several antiapoptotic proteins through STAT3 [13]. Our
data indicate that IL-6 expression was linked with
Figure 5 (See legend on next page.)
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Figure 5 IL-6 is linked to MDSC recruitment. Effects of IL-6 and irradiation on MDSC recruitment in tumors were evaluated by (a) FACS of
spleen using GrI-CD11b staining, and (b) immunofluorescence of tumor (DAPI, blue; CD11b, red) in mice bearing tumors (tumor size 300 ~
350 mm3) with or without IL-6–silencing vectors or 48 h after 15-Gy irradiation or sham-irradiation. Representative images are shown.
Quantification of CD11b expression was calculated as the number of cells positive for CD11b immunofluorescence divided by the total number
of cells for each condition. Y-axis represents the ratio normalized to the value of TRAMP-C1 cells. Columns are the means of three independent
experiments; bars, SD. *, P < 0.05. The effect of IL-6 on MDSC recruitment was further evaluated by (c) FACS of the spleen and (d)
immunofluorescence of tumor specimens in pre-irradiated mice bearing tumors (with or without IL-6 stimulation) for 2 weeks.
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ation for prostate cancer. When IL-6 was inhibited by
the silencing vector, increased RT-induced cell death
associated with increased RT-induced ROS and oxidative
DNA damage was observed. Moreover, IL-6 inhibition
was shown to decrease the level of p-STAT3 and
increase those of p53 and p-H2AX in both TRAMP-C1
and HR cancer cells after irradiation. We found that a
significant decrease in the expression of p53 was noted
in HR cells, and associated with radiation resistance
[21]. P53 has been reported to play an important role in
ROS scavenging and DNA repair, and may contribute to
the increased cell death and radiosensitivity [21,33].
Moreover, several studies revealed that the reduced p53
could induce prostate cancer cells to become androgen
unresponsive and decrease the apoptosis induced by
androgen deprivation [34,35]. Activated STAT3 was
reported to bind to p53 and represses its function as a
regulator of apoptosis [36]. Accordingly, we suggest that
the decreased STAT3 activation and ROS scavenging
ability associated with increased apoptosis and p53 levels
contributes to the IL-6–silencing-vector induced radio-
sensitization in prostate cancer, at least in part.
Radiation therapy is widely used to achieve locore-
gional control of cancers. Unfortunately, the initial
tumor response is often followed by a relapse. For
decades, studies have focused on the radiosensitivity of
cancer cells. It is becoming increasingly clear that mul-
tiple changes in tumor stroma may also determine the
treatment outcome. Tumor regrowth after radiotherapy
may be substantially affected by systemic factors. The
gold standard for assessment of the clinical efficacy of a
particular treatment in vivo is the long-term response of
tumors using mouse models. Tumor responsiveness to
treatment is influenced both directly and indirectly by
the vasculature and tumor cell proliferation. To inves-
tigate the mechanisms underlying tumor regrowth in
prostate cancer, we pre-irradiated the prostate and lower
extremities of mice with a single 10-Gy dose before
implanting prostate cancer cells to mimic local relapse
after radiotherapy. IL-6/STAT3 signaling was reported to
stimulating tumor invasion, EMT changes, and promote
the surviving tumor cells after therapy to acquire treat-
ment resistance [37] via microenvironment- mediated
resistance. Increased IL-6 in LNCaP-IL-6+ cancer cellsshowed a growth advantage, STAT3 activation, high
expression of VEGF association with androgen-
independent growth [38,39]. In the present study, tumor
growth combined with IF and IHC data using VEGF, Ki-
67, and CD31 staining, suggest that the IL-6–silencing
vector slowed tumor regrowth and attenuated the
aggressive behavior of the orthotopic tumor model,
which were associated with decreased STAT3 activation,
cell proliferation and angiogenesis following irradiation.
Therefore, in addition to increased cell death, slower
tumor regrowth associated with attenuated angiogenesis
may contribute, in part, to the radiosensitization induced
by IL-6 inhibition in vivo.
Ionization radiation intensifies the recruitment of dis-
tal stroma, in the form of inflammatory bone-marrow-
derived cells, to the tumor and its surroundings.
Furthermore, relapses within a pre-irradiated area are
associated with an increased risk of local invasion and
metastasis formation in several cancers. MDSC are an
important subset of cells that contribute to an immuno-
suppressive tumor microenvironment, and are reported
to facilitate tumor regrowth after irradiation [17,40]. We
reported previously that MDSCs might be responsible
for tumor promotion by IL-6 in prostate cancer. More-
over, we identified a positive correlation between circu-
lating IL-6 level and tumor regrowth in irradiated mice
with prostate cancer. Therefore, we further examined
the link between MDSC and circulating IL-6 in tumor
relapse post-irradiation. Irradiation increased MDSC
recruitment in tumor-bearing mice. Furthermore, there
was a positive correlation between the MDSC subpopu-
lation and IL-6 levels in the mouse tumors. IL-6–silen-
cing vectors significantly reduced MDSC infiltration,
and IL-6 stimulation had a positive impact on MDSC
recruitment. These findings suggest that IL-6 plays a
critical role in MDSC recruitment and tumor regrowth
after irradiation.
In summary, IL-6 inhibition sensitizes tumor cells to
irradiation, increasing cell death and DNA damage, and
mitigates tumor regrowth after irradiation by eliminating
RT-triggered MDSC infiltration and angiogenesis. Thus
the IL-6 level might be significant predictor of the
radiation response in prostate cancer. In future, we will
further determine if targeting IL-6 is a useful strategy for
sensitizing prostate cancer to irradiation.
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